Herceptin (trastuzumab), and For more information, please review the PERJETA Important Safety Information and the full Prescribing Information.
Mepolizumab US prescribing information. Available from: Herceptin (trastuzumab), for the Treatment of Several Forms of
Find product and prescribing information, as well as other resources, for Genentech's oncology portfolio below. Herceptin. (trastuzumab). Prescribing
1.14.1.3 . Final Labeling Text HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use Herceptin safely and effectively.
HERCESSI (trastuzumab-strf) is biosimilar to HERCEPTIN (trastuzumab). See full prescribing information for complete boxed warning.
Herceptin [prescribing information]. South San Francisco, CA: Genentech, Inc.; February 2024. 2. Herzuma [prescribing information]. North Wales, PA: Teva
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information for Herceptin. HERCEPTIN (trastuzumab) for injection, for intravenous use Initial U.S. Approval: 2024 WARNING: CARDIOMYOPATHY, INFUSION REACTIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information for Herceptin. HERCEPTIN (trastuzumab) Intravenous Infusion Initial U.S. Approval: 2024 . WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY
HERCEPTIN HYLECTA safely and effectively. See full prescribing information for HERCEPTIN HYLECTA. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) injection, for subcutaneous use Initial U.S. Approval: 2024 WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning.
Comments